Burlington, Mass.– Bone Biologics Corporation (Nasdaq: BBLG, BBLGW), a company focused on developing orthobiologic products for spinal fusion, has announced the pricing of a $5 million public offering. The offering includes 1.25 million shares of common stock—or equivalent securities—and accompanying Series D and Series E warrants, all priced at $4.00 per unit.
Each unit comprises one share of common stock (or a common stock equivalent), a Series D warrant, and a Series E short-term warrant. Both types of warrants are exercisable immediately. The Series D warrants will expire in five years, while the Series E warrants have an 18-month term. If fully exercised for cash, the warrants could generate an additional $10 million in gross proceeds, though the company notes there is no guarantee they will be exercised.
The offering is expected to close on or around June 30, pending standard closing conditions. H.C. Wainwright & Co. is acting as the sole placement agent.
Bone Biologics plans to use the proceeds to advance clinical trials, bolster its intellectual property portfolio, and support working capital and general operations.
The offering is being conducted under a registration statement declared effective by the U.S. Securities and Exchange Commission (SEC) on June 27, 2025. Interested investors can access the final prospectus through the SEC’s website or by contacting H.C. Wainwright & Co. directly.
Bone Biologics specializes in regenerative solutions for orthopedic spine surgery, aiming to improve outcomes for patients undergoing spinal fusion procedures.
